PT - JOURNAL ARTICLE AU - Smith, Emily R. AU - He, Siran AU - Oakley, Erin AU - Miller, Lior AU - Tielsch, James M. TI - Protocol for a Sequential, Prospective Meta-Analysis to Describe COVID-19 in Pregnancy and Newborn Periods AID - 10.1101/2020.11.08.20228056 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.08.20228056 4099 - http://medrxiv.org/content/early/2020/11/12/2020.11.08.20228056.short 4100 - http://medrxiv.org/content/early/2020/11/12/2020.11.08.20228056.full AB - Background We urgently need answers to basic epidemiological questions regarding COVID-19 infection in pregnant women and newborns. While many national registries, health facilities, and research groups are collecting relevant data, we need a collaborative and methodologically appropriate approach to utilize these data to generate answers.Methods We propose that a sequential, prospective meta-analysis (PMA) is the best approach to rapidly generate policy and practice-oriented guidelines. As the pandemic is rapidly evolving, studies identified retrospectively through a living systematic review will also be invited to participate. The primary analysis will pool data using a two-stage meta-analysis with generic inverse-variance methods. The meta-analyses will be updated as additional data accrues in each contributing study and as additional studies meet study-specific time or data accrual thresholds for sharing.Participating Studies At the time of publication, there are 19 studies being conducted in 21 countries that prospectively agreed to pool data for this analysis. Among the 19 included studies, ten are COVID-19 registry studies, seven are cohort or surveillance studies, and two are case-control studies. More than 74,000 pregnant women are expected to contribute to the completed analysis.Dissemination Protocols and updates will be maintained publicly. Results will be shared with key stakeholders including the World Health Organization (WHO) Maternal, Newborn, Child, and Adolescent Health (MNCAH) Research Working Group. Scientific publications will be published in open access journals on an ongoing basis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialPROSPERO ID: 188955Funding StatementFunded by the Bill & Melinda Gates Foundation grant to Emily Smith (INV-022057) at George Washington University and a grant to Emily Smith via a grant from the Bill & Melinda Gates Foundation to Stephanie Gaw (INV-017035) at University of California San Francisco.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a protocol paper and thus exempt from ethical approval. Ultimately, the meta-analysis study is exempt from human research ethics approval as the study authors will be synthesizing de-identified or aggregate data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol paper and there is no related data to share.